NAS
TRVI icon

Nykredit A/S’s Trevi Therapeutics TRVI Stock Holding History

Nykredit A/S’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.8K Buy
+1,168
New +$17K ﹤0.01% 1713

Other funds holding TRVI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return

Nykredit A/S's TRVI Position: Q2 2026 in Review

Nykredit A/S opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 1,168 shares worth $21.8K. The stake represents ﹤0.01% of the portfolio and ranks #1713 among its holdings.

132 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Nykredit A/S held 1,168 shares of Trevi Therapeutics worth $21.8K as of Q2 2026.
  • Trevi Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Trevi Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1713 holding.
  • 132 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.